Journal
JOURNAL OF HEMATOLOGY & ONCOLOGY
Volume 11, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s13045-018-0679-0
Keywords
Myelomas; WES; Tumor suppressors; DNA repair; Fanconi pathway
Categories
Funding
- FFRMG
- Action Cancer 44
- DHU Oncogreffe
- Ligue Grand Ouest contre le Cancer
- SIRIC ILIAD [INCa-DGOS-Inserm_12558]
- L'Hema-NexT (i-site NexT)
- INSERM (poste d'accueil)
- Fondation ARC
- SyMeTRIC project - Region Pays de la Loire Connect Talent research call
Ask authors/readers for more resources
BackgroundHuman myeloma cell lines (HMCLs) are widely used for their representation of primary myeloma cells because they cover patient diversity, although not fully. Their genetic background is mostly undiscovered, and no comprehensive study has ever been conducted in order to reveal those details.MethodsWe performed whole-exon sequencing of 33 HMCLs, which were established over the last 50years in 12 laboratories. Gene expression profiling and drug testing for the 33 HMCLs are also provided and correlated to exon-sequencing findings.ResultsMissense mutations were the most frequent hits in genes (92%). HMCLs harbored between 307 and 916 mutations per sample, with TP53 being the most mutated gene (67%). Recurrent bi-allelic losses were found in genes involved in cell cycle regulation (RB1, CDKN2C), the NFB pathway (TRAF3, BIRC2), and the p53 pathway (TP53, CDKN2A). Frequency of mutations/deletions in HMCLs were either similar to that of patients (e.g., DIS3, PRDM1, KRAS) or highly increased (e.g., TP53, CDKN2C, NRAS, PRKD2). MAPK was the most altered pathway (82% of HMCLs), mainly by RAS mutants. Surprisingly, HMCLs displayed alterations in epigenetic (73%) and Fanconi anemia (54%) and few alterations in apoptotic machinery. We further identified mutually exclusive and associated mutations/deletions in genes involved in the MAPK and p53 pathways as well as in chromatin regulator/modifier genes. Finally, by combining the gene expression profile, gene mutation, gene deletion, and drug response, we demonstrated that several targeted drugs overcome or bypass some mutations.ConclusionsWith this work, we retrieved genomic alterations of HMCLs, highlighting that they display numerous and unprecedented abnormalities, especially in DNA regulation and repair pathways. Furthermore, we demonstrate that HMCLs are a reliable model for drug screening for refractory patients at diagnosis or at relapse.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available